GADD45A and glioblastoma: Given that GADD45A is not a frequent target of mutations in cancers and that no reports of GADD45A mutations in GBM have been published to date29, this protective role of GADD45A against TMZ may be applied to the development of additional local therapeutics for use along with systemic TMZ treatment in GBM patients and may provide a new therapeutic prospect for GBM treatment.